Market Watch: Mesoblast shares down 14%
Monday, 31 October, 2011
The share price of stem cell specialists Mesoblast (ASX:MSB) shed 14% of its value in trading on Friday and today, down from $9.39 at Thursday’s close of trading to $8.25 as of midday today.
The drop was precipitated by Macquarie Research updating its rating for the biotech to “underperform”.
Other analysts have recently rated Mesoblast as “buy”, with Nomura setting a target price of $10.15 and Bell Potter $16.00 both only one month ago.
Late last year Mesoblast wowed the industry with its monumental deal with Cephalon, and recently announced it was partnering with Lonza to manufacture it’s off-the-shelf mesenchymal precursor stem cells.
Follow this link for a detailed profile of Mesoblast and its technology, and an interview with its CEO, Professor Silviu Itescu.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
